Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

  title={Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer},
  author={Woonyoung Choi and Bogdan A Czerniak and Andrea Ochoa and Xiaoping Su and Arlene O Siefker-Radtke and Colin P. N. Dinney and David McConkey},
  journal={Nature Reviews Urology},
Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are heterogeneous and can be grouped into basal and luminal subtypes that are highly reminiscent of those found in breast cancer. Basal MIBCs are enriched with squamous and sarcomatoid features and are associated with advanced stage and metastatic disease at presentation. Like basal breast cancers, basal bladder tumours contain a claudin-low subtype that is enriched with biomarkers characteristic of epithelial-to… 
Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer
The results strongly suggest that miRNAs contribute to the control of the gene expression patterns observed in basal and luminal MIBCs and that they can be used as biomarkers and candidate therapeutic targets.
Subtype-specific epigenomic landscape and 3D genome structure in bladder cancer
A subtype-specific epigenomic and 3D genome structure in urinary bladder cancers is shown and a novel link between the circadian TF NPAS2 and a clinical bladder cancer subtype is suggested.
Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer
This work identifies unique epigenomic signatures and 3D genome structures in luminal and basal urinary bladder cancers and suggests a novel link between the circadian transcription factor NPAS2 and a clinical bladder cancer subtype.
Genetic subtypes of invasive bladder cancer
It seems likely that prospective identification of tumor intrinsic subtype membership could complement the use of DNA-based biomarkers to identify the groups of patients who will benefit the most from chemotherapy and targeted agents.
FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
This analysis identified a set of human cell lines suitable for the study of molecular subtypes in bladder cancer, and indicates a cooperative regulatory network consisting of GATA3, FOXA1, and PPARɣ drive luminal cell fate.
Assessment of Luminal and Basal Phenotypes in Bladder Cancer
A quantitative classifier referred to as basal to luminal transition (BLT) score is developed which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity.
Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes
The genetics commonness between MIBC and breast cancers from the molecular heterogeneity based on the disease subtypes was explored and some basal-related and luminal-related genes shared by two cancers were identified.
Origins of Bladder Cancer.
New research developments hold the promise of expanding the armamentarium of diagnostic and treatment options for patients with bladder cancer and improving the ability to select patients most likely to respond to a specific therapy.
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Genomic analyses revealed that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of cell cycle and EMT networks, and nearly half exhibited a heavily infiltrated immune phenotype.


Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Evidence is presented that there are two intrinsic subtypes of high-grade bladder cancer, basal-like and luminal, which reflect the hallmarks of breast biology and an accurate gene set predictor of molecular subtype, the BASE47, that should allow the incorporation of subtype stratification into clinical trials.
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
It is confirmed that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.
Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.
This study created a novel transgenic mouse model of invasive bladder cancer by targeting an active dimerized form of Stat3 to the basal cells of bladder epithelium and shows that Stat3-induced stem cell expansion plays a critical role in the unique clinical progression ofvasive bladder cancer through the CIS pathway.
p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers
The data confirm that molecular markers of EMT are elevated in muscle-invasive bladder cancers, but interestingly, retention of the “epithelial” marker p63 in Muscle-in invasive tumors is associated with a worse outcome.
Comprehensive molecular portraits of human breast tumors
The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Bladder cancer outcome and subtype classification by gene expression.
  • E. Blaveri, J. Simko, F. Waldman
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
The isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary human bladder cancer is described, based on the expression of markers similar to that of normal bladder basal cells, which effectively distinguishes muscle-invasive bladder cancer with worse clinical prognosis from non-muscle-in invasive (superficial) cancer.
Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma
The spatially restricted epithelial differentiation program described here represents a conceptual advance in understanding cellular heterogeneity of carcinomas and identifies basal‐like HTCs as attractive targets for cancer therapy.